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Abstract. Background: Selection of the human drug sensitive
and invasive cell line (MDA-MB-435S-F) with the
chemotherapeutic agent paclitaxel, resulted in the development
of drug resistant cell lines displaying enhanced invasion-related
characteristics. Materials and Methods: Serum-free conditioned
media from the human cancer drug-sensitive and invasive cell
line (MDA-MB-435S-F) and its paclitaxel-resistant superinvasive
variant (MDA-MB-435S-F/Taxol10p4pSI) were analyzed using
Surface enhanced laser desorption/ionization time-of-flight mass
spectrometry (SELDI-TOF MS). Results: A differentially
expressed protein was observed at 7.6 kDa, which was 4-fold up-
regulated in MDA-MB-435S-F/Taxol10p4pSI. The differentially
expressed protein was identified using matrix-assisted laser
desorption ionization tandem time-of-flight mass spectrometry
(MALDI-TOF/TOF MS), as a fragment of bovine transferrin.
The transferrin receptor was also found to be overexpressed in the
superinvasive cell line. Conclusion: Cleavage of serum proteins
such as transferrin could provide a valuable source of markers
for malignant tumours and could also play a role in aspects of
cancer pathogenesis, such as tumour cachexia. 
The development of invasive and metastatic behaviour
during cancer progression requires the concerted action of
multiple genes and cellular functions, including cytoskeleton
remodeling, acquisition of migratory phenotypes, ability to
invade the tumour surrounding tissues, and survival of
disseminated tumour cells. There is evidence in the literature
that invasion and metastasis may sometimes be related to the
multidrug resistance (MDR) phenotype (1). In some cases,
invasive/metastatic cells develop drug resistance more readily
than non-invasive/metastatic cells (2, 3). Some tumour cell
lines selected for resistance to chemotherapeutic drugs are
more invasive/metastatic relative to non-resistant parental
cells (4-8). However the possible relationship between drug
resistance and invasion/metastasis and how prevalent this
phenotype is remains poorly understood, especially from a
proteomics perspective.
Surface enhanced laser desorption/ionization time-of-
flight mass spectrometry (SELDI-TOF MS) is a relatively
new proteomics technology for the analysis of serum,
plasma, intestinal fluid, urine, cell lysates and cellular
secretions focusing on the discovery and identification of
potential biomarkers for various diseases. SELDI-TOF MS
utilizes the different chromatographic properties of
ProteinChip® arrays from Ciphergen to bind different
subsets of peptides and proteins for subsequent analysis (9).
Recent reports employing SELDI-TOF MS-based approach
have demonstrated that protein profiles are useful for the
early detection of breast, prostate and colon cancers (10-
12). Distinct protein profiles of many carcinoma cell lines
and associated variants are now established using this
technology (13, 14). More recently, SELDI-TOF MS-based
serum profiling has been subject to criticism, with results
published by some groups not being reproduced by others
(15-18). However, the same level of criticism may not apply
to cell culture based SELDI-TOF MS analysis since
multiple replicate samples from the same cell line are
readily obtainable.
Paclitaxel (MDA-MB-435S-F/Taxol10p4pSI)-selected
variants of an in vitro invasive clonal population of the
human breast cancer cell line, MDA-MB-435S-F, were
established by pulse selection, and exhibited a novel
‘superinvasive' phenotype (19). This phenotype is
characterized by an ability to relocate to another surface
following invasion through matrigel and membrane pores.
Decreased adhesion to extracellular matrix proteins and
increased motility are also typical of this phenotype. This
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may represent an in vitro model of a step in the metastatic
process occurring subsequent to invasion. 
The secretome of cells and tissues may reflect a broad
variety of pathological conditions and thus represents a rich
source of information. In order to investigate changes in the
secretome that might be associated with mechanisms involved
in drug resistance and invasion/metastasis, or for establishing
biomarkers associated with this phenotype, conditioned
media from the parental cell line, MDA-MB-435S-F and the
drug-selected superinvasive population, MDA-MB-435S-
F/Taxol-10p4pSI were subject to biochemical and proteomic
analysis.
Materials and Methods
Chemicals. All media and serum used in the maintenance of the
cell lines were obtained from Sigma Aldrich (Dublin, Ireland).
Chemicals were obtained from Sigma (Dublin, Ireland) and
IMAC30 ProteinChip Arrays, IMAC Hypercel spin columns and
sinapinic acid from (Ciphergen Biosystems, CA, USA).
Cell lines. The human breast cancer cell line MDA-MB-435S was
obtained from the American Type Culture Collection (ATCC) and
was maintained in culture at 37ÆC using RPMI 1640 media
supplemented with 2 mM L-glutamine (Gibco BRL, Grand Island,
NY, USA) and 10% foetal calf serum. 
MDA-MB-435S has a spindle-shaped morphology which evolved
from the parental line MDA-MB-435 isolated by Cailleau et al.
(20), and was originally derived from the pleural effusion of a 31-
year-old female with metastatic, ductal adenocarcinoma of the
breast. Recently, the tissue origin of MDA-MB-435 cell line has
been the subject of considerable debate. In 2002, results were
published suggesting that MDA-MB-435 was of melanoma origin
(21). It was recently reported that the MDA-MB-435 cells used
widely have identical origins to those that exhibit a melanoma-like
gene expression signature, but exhibit a small degree of genotypic
and phenotypic drift (22), but the possibility that some breast
tumours may have gene expression profiles similar to melanoma
cannot be ruled out.
Cell culture. MDA-MB-435S-F was obtained by clonal dilution from
MDA-MB-435S in this laboratory. The MDA-MB-435S-F
paclitaxel-resistant variant was derived by pulse selection of the
parental cells with the IC90 value of doxorubicin or paclitaxel. Cells
were exposed to the IC90 value of 15 ng/ml paclitaxel for 4 h, once
a week for 10 weeks (MDA-MB-435S-F/Taxol-10p). These cells
were then exposed to 125 ng/ml paclitaxel for 4 h, once a week for
4 weeks (MDA-MB-435S-F/Taxol-10p4p). Antibiotics were not
used in the growth media. All cell lines were free from mycoplasma
as tested with the indirect Hoechst DNA staining method (19).
Invasion assays. Invasion assays were performed by a modification
of the method described by Albini et al. (23). Matrigel was diluted
to 1 mg/ml in serum-free RPMI medium then 100 Ìl of 1 mg/ml
Matrigel (Sigma, Dublin, Ireland) was placed into each insert
(Falcon, Franklin Lakes, NJ, USA) (8.0 Ìm pore size), which stood
in wells of a 24-well plate (Bio-Rad Labs., Hemel Hempstead,
Herts., UK). The inserts and the plate were incubated overnight at
4ÆC. The following day, cells were harvested and suspended in
RPMI-1640 containing 10% FCS at a concentration of 1x106
cells/ml. The inserts were washed with serum-free RPMI-1640 then
100 Ìl of the cell suspension was added to each insert and 250 Ìl of
RPMI-1640 containing 10% FCS was added to the insert well. Cells
were incubated at 37ÆC for 48 h. After this time period, the inner
side of the insert was wiped with a wet swab to remove the cells,
while the outer side of the insert was gently rinsed with PBS and
stained with 0.25% crystal violet for 10 min, rinsed again and then
allowed to dry. The surface of the 24-well plate was rinsed gently
twice with PBS and stained with 0.25% crystal violet for 10 min,
rinsed again and then allowed to dry. Cells were quantified by
counting with the aid of a light microscope. 
Isolation of MDA-MB-435S-F/Taxol-10p4pSI cell populations. The
superinvasive populations, (SI’s) were isolated by allowing cells to
grow which had invaded, detached from the bottom of the insert
and re-attached to the bottom of the 24-well plate, until they
reached suitable confluency levels for further subculturing.
Preparation of serum-free conditioned media. Cells were grown to
60-70% confluency in RPMI-1640 media supplemented with 2 mM
L-glutamine (Gibco BRL, Grand Island, NY, USA) and 10% foetal
calf serum and then washed three times in serum-free medium.
Cells were subsequently incubated in serum-free medium for 1 h,
washed two more times in serum-free medium, then incubated in
serum free media for 72 h. Conditioned medium was collected,
centrifuged at 1000 rpm for 15 min to remove cellular debris,
decanted into clean tubes and stored at –80ÆC.
Surface enhanced laser desorption/ionization time-of-flight mass
spectrometry (SELDI-TOF-MS). Conditioned medium was
concentrated using 3000 MW cut-off centricons (Millipore,
Billerica, MA, USA). Samples were then diluted with 250 mM
sodium chloride. An IMAC30 ProteinChip Array, 8-spot
(Ciphergen Biosystems, CA, USA) was selected for this study.
IMAC30 chips were coated with 5 ÌL of 100 mM CuSO4 for a total
of 30 min (2x15 min applications) and then rinsed with high-
performance liquid chromatography grade water (Sigma, Dublin,
Ireland). The copper ions were charged by applying 50 Ìl of 100
mM sodium acetate for 5 min. The chip was placed in a
bioprocessor (Ciphergen) and washed twice with 300 Ìl of 250 mM
sodium chloride then 350 Ìl of the diluted sample were applied to
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Figure 1. Levels of superinvasion are displayed for MDA-MB-435S-F and
MDA-MB-435S-F/Taxol-10p4pSI. Results are displayed as the mean
number of cells invading ± s.d. (n=3).
the spots of the array. The array was placed on a shaker and gently
agitated for 90 min to allow for interaction with the array surface.
After removing the sample, the array was washed twice with 300 Ìl
of 250 mM sodium chloride for 5 min, followed by a brief high
performance liquid chromatography grade water wash. After
removing the array from the bioprocessor, a 0.8 Ìl aliquot of
saturated sinapinic acid (SPA; dissolved in 50% acetonitrile
containing 0.5% trifluoroacetic acid) was added to the spots,
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Figure 2. (A) Chromatographic view of the conditioned media from the human cancer drug-sensitive and invasive phenotype MDA-MB-435S-F and its
paclitaxel-resistant superinvasive variant MDA-MB-435S-F/Taxol10p4pSI run in triplicate on IMAC30-Cu2+ ProteinChip Arrays. The arrow indicates the
position of a differentially expressed species at approximately 7.6 kDa. (B) 1D-Gel view of the corresponding chromatographs. The 7.6 kDa species was
found to be fourfold up-regulated in MDA-MB-435S-F/Taxol10p4pSI cells.
allowed to dry and the application repeated. The IMAC30-Cu2+
ProteinChip Arrays were then analyzed in a Ciphergen Series PBS-
IIC ProteinChip® System (SELDI mass spectrometer) and TOF
data generated by averaging a total of 220 laser shots collected at a
laser intensity of 200, a detector sensitivity of 8 and molecular mass
range from 0-20000 Da.
Analysis of SELDI spectra. Data were analyzed using Biomarker
Wizards Software (Ciphergen Biosystems). After automatic
baseline noise correction, the spectra were normalized by the ‘‘total
ion content’’ method as described by the manufacturer. The peaks
with an m/z value <2 kDa were excluded, as these peaks were
mainly ion noise from the matrix (sinapinic acid). Peak clusters
were generated by automatically detecting qualified mass peaks
(S/N>5) then completed with second-pass peak selection (S/N>3,
with a 0.3% mass window). 
Protein purification. To fully characterize the 7.6-kDa protein,
conditioned media from the MDA-MB-435S-F/Taxol 10p4pSI
population was fractionated first using BioSepra IMAC-Cu2+
HyperCel spin columns (BioSepra, Cergy, France). Each of the
fractions eluted from the spin columns using 50 to 500 mmol/l
imidazole in binding buffer containing 250 mM sodium chloride was
analyzed further on a hydrophilic NP20 ProteinChip Array (1 Ìl per
spot) to monitor the elution and recovery of the protein of interest.
The eluted fractions in which the marker was the most abundant were
concentrated to 30 Ìl using 3000 MW cut-off centricons (Millipore,
Billerica, MA, USA) and were loaded onto 4-12% NuPAGE Bis-Tris
Gels (Invitrogen, NY, USA) and run using a MES/SDS buffer. The
samples were run according to the manufacturer's instructions and
were stained using Invitrogen SilverQuest protocols.
MALDI TOF/TOF MS and protein identification. In-gel digestion of
proteins was carried out following a modified protocol from
Schevchenko et al. (24). Milli-Q water (200 Ìl) was added to the
excised gel piece and placed on a shaker for 15 min. Acetonitrile
(200 Ìl) was then added and incubated with shaking for a further
15 min. The solution was then removed and replaced with 200 Ìl
100 mM NH4HCO3 and left to shake for 15 min after which the
solution was replaced with 200 Ìl 100 mM NH4HCO3 in 50%
acetonitrile and left for a further 15 min with shaking. This solution
was removed and 100 Ìl of acetonitrile was added; following
incubation on a shaker for 10 min, the solution was then removed
and the gel piece was dried in a SpeedVac concentrator (Thermo
Fisher Scientific, MA, USA) for 10 min. Fifty Ìl of 10 mM
dithiothreitol in 20 mM NH4HCO3 was added to gel piece which
was then placed at 56ÆC for 1 h after which the liquid was removed
and replaced with 50 Ìl of 50 mM iodoacetamide in 20 mM
NH4HCO3. This was left at room temperature, in the dark with
shaking for 30 min. Gel pieces were then washed again with
subsequent solutions of 100 mM NH4HCO3, 100 mM NH4HCO3
in 50% acetonitrile and 100 Ìl acetonitrile, as previously, and the
gel piece was dried in a SpeedVac concentrator for 10 min.
Gel slices were rehydrated with trypsin digestion buffer with
enough liquid to cover each gel piece (12.5 Ìg/ml modified bovine
trypsin (Roche, NJ, USA), 0.1% n-octyl glucoside (Calbiochem,
San Diego, CA, USA) and 20 mM NH4HCO3). After 16 h
incubation on a shaker at 30ÆC, an equal volume of acetonitrile
was added and the peptides were allowed to extract for 10 min with
shaking. One tenth of the peptide solution from the digest was
added to a 192 spot MALDI sample plate (Applied Biosystems,
Warrington, UK) and supplemented with 0.5 Ìl of a 5 mg/ml
solution of recrystalised ·-cyano-4-hydroxy-trans-cinnamic acid
matrix (Sigma) plus 10 mM NH4H2PO4 in 50% acetonitrile/water
containing 0.1% TFA and allowed to air dry prior to analysis.
MALDI mass spectra were generated using a 4700 TOF/TOF
Proteomics Analyzer instrument (Applied Biosystems). Prior to
analysis, the instrument was externally calibrated using the 4700
Proteomics Analyzer Calibration Mixture (4700 Cal Mix; (Applied
Biosystems). All MS and MS/MS experiments were carried out in
positive reflectron mode. Five precursor ions for MS/MS were selected
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Figure 3. Biomarker wizard cluster view of MDA-MB-435S-F and its paclitaxel-resistant superinvasive variant MDA-MB-435S-F/Taxol10p4pSI.
automatically on the basis of intensity from the MS spectra. The MS
and MS/MS data were combined and searched against a number of
databases using GPS Explorer software (Applied Biosystems) and a
local MASCOT (Matrix Science, MA, USA) search engine for protein
identification. A mass window of 20 ppm was set for database
searching on all precursors. All mass spectrometry and protein
identification was performed with "FingerPrints", Wellcome Trust
Biocentre, University of Dundee, Scotland.
Immunoblot analysis. Electrophoretic transfer of proteins to
Hybond-ECL nitrocellulose membranes (Amersham, Bucks., UK)
was carried out using a Bio-Rad Transblot SD cell (Bio-Rad Labs.,
Hemel Hempstead, Herts., UK). Proteins were transferred for 80
min at 0.34 mA. Efficiency of transfer was evaluated using
Ponceau-S-Red staining of nitrocellulose membranes, followed by
destaining in phosphate buffered saline (PBS; 50 mM sodium
phosphate, 0.9% (w/v) NaCl, pH 7.4). Membranes were blocked
for 1 h in 5% (w/v) fat-free milk powder in PBS containing 0.5%
Tween-20. Membranes were then incubated overnight at 4ÆC with
the primary antibody, anti-transferrin receptor (Abcam,
Cambridge, UK; ab1086) diluted to 1:1000 with blocking buffer.
Nitrocellulose replicas were subsequently twice washed for 10 min
in blocking solution and then incubated with a 1:1000 dilution of
the corresponding peroxidase-conjugated secondary antibody for 1
h at room temperature (DakoCytomation, Glostrup, Denmark).
Nitrocellulose membranes were washed twice for 10 min in
blocking solution and twice rinsed for 10 min in PBS. Visualization
of immuno-decorated 1D bands was carried out using an enhanced
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Figure 4. IMAC-Cu2+ Hypercel fractionation of MDA-MB-435S-F/Taxol10p4pSI using increasing concentrations of Imidazole. All seven fractions collected
from unbound peptides/proteins through to 500 mM Imidazole were analysed on NP20 ProteinChip Arrays. From the chromatographs it is clear that the
greatest concentration of the 7.6 kDa species elutes in the 250 mM fraction with the majority of the contaminating proteins removed in earlier fractions.
chemiluminescence kit (Amersham). The immunoblots were
subsequently scanned and densitometric analysis performed using
Labworks 302 software (Labworks, CA, USA).
Results
Invasion assay. MDA-MB-435S-F was highly invasive, but
selection with paclitaxel resulted in a more aggressive invasive
phenotype characterized by a proportion of the invading cells
detaching from the bottom of the insert and reattaching to
the bottom of the 24-well plate (superinvasion), which was
negligible in MDA-MB-435S-F as shown in Figure 1.
Expression difference mapping analysis. A total of 98 peaks
were detected and 5 peaks were found to be differentially
expressed with statistical significant p-value of <0.05. The
most prominent differentially expressed peak at m/z 7.6 was
found to be fourfold greater in the superinvasive phenotype
with a statistically significant p-value of <0.04. Figure 2(A)
shows comparative chromatographs of mass signals and
Figure 2(B) shows the one-dimensional gel view. Figure 3
shows the Biomarker Wizard plot from conditioned media
analyzed on IMAC30-Cu2+ ProteinChip arrays. Conditioned
media from MDA-MB-435S-F and MDA-MB-435S-
F/Taxol10p4pSI were analyzed in triplicate using IMAC30-
Cu2+ chip surface. Results were cross-checked for their
reproducibility by using different biological sample and
replicates on different ProteinChip batches. 
Purification of the 7.6-kDa marker candidate. The IMAC
HyperCel sorbent has greater capacity than an IMAC30
ProteinChip Array and is used where enrichment of the
target protein is desired. The conditioned media from
MDA-MB-435S-F/Taxol-10p4pSI cells was fractionated
using BioSepra IMAC-Cu2+ HyperCel spin columns, with
the 250 mM Imidazole fraction showing the highest
concentration of the 7.6-kDa protein along with the least
number of contaminating peaks (Figure 4). The 250 mM
fraction was run on a 4-12% NuPAGE Bis-Tris 1D gels
using a MES/SDS running buffer and antioxidant under
reducing conditions. The MES/SDS running buffer is
specially formulated for greater resolution in the lower
molecular weight range. Silver staining of the gel allowed a
band at 7.6 kDa to be excised.
Identification of the 7.6-kDa marker candidate. In-gel digestion
of proteins was carried out using a modified version of the
method used by Schevchenko et al. (24). Tryptic digests of the
two proteins were subject to MALDI TOF/TOF analysis. All
MS and MS/MS experiments were carried out in positive
reflectron mode. Five precursor ions for MS/MS were
selected automatically on the basis of intensity from the MS
spectra. The MS and MS/MS data were combined and
searched against a number of databases and identified as a
7.6-kDa protein fragment of bovine transferrin. 
Immunoblot analysis of MDA-MB-435S-F and MDA-MB-
435S-F/Taxol10p4pSI cells. Immunoblot analysis of whole
cell lysates from both MDA-MB-435S-F and MDA-MB-
435S-F/Taxol10p4pSI phenotypes using an antibody against
the transferrin receptor showed a marked increase in the
abundance levels of the receptor in MDA-MB-435S-
F/Taxol10p4pSI cells. The transferrin receptor was found to
be approximately 3.5-fold increased in the superinvasive
phenotype compared to the parent (Figures 5 and 6). This
3.5-fold increase in the receptor corresponds to a fourfold
increase in the transferrin fragment identified using SELDI
analysis found in the MDA-MB-435S-F/Taxol10p4pSI
conditioned media (Figure 6). 
Discussion
To identify patterns of differential expression that may
correlate with the drug-selected superinvasive phenotype
exhibited by MDA-MB-435S-F/Taxol-10p4pSI, conditioned
media was subject to SELDI-TOF MS analysis. Initial
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Figure 5. Coomassie blue stained NuPAGE gel showing equal protein
loading from both MDA-MB-435S-F and its paclitaxel-resistant
superinvasive variant MDA-MB-435S-F/Taxol10p4pSI. This gel is
representative of repeat experiments. Western blot analysis of MDA-MB-
435S-F and MDA-MB-435S-F/Taxol10p4pSI probed with a transferrin
receptor antibody showing the increase in abundance of the 190 kDa
protein in the MDA-MB-435S-F/Taxol10p4pSI phenotype. This Western
blot is representative of repeat experiments.
analysis carried out using the IMAC30-Cu2+ ProteinChip
arrays demonstrated that the expression level of the 7.6 kDa
protein in MDA-MB-435S-F/Taxol-10p4pSI cells was
increased when compared with MDA-MB-435S-F cells. The
7.6-kDa protein was found to be 4-fold up-regulated in the
superinvasive taxol-resistant cells with a statistically
significant p-value of <0.04. 
Purification and identification of the 7.6 kDa was
performed using conditioned media from the MDA-MB-
435S-F/Taxol-10p4pSI population and using MALDI
TOF/TOF analysis was identified as a 7.6-kDa protein
fragment of bovine transferrin. 
Plasma transferrin is an 80-kDa glycoprotein with
homologous N-terminal and C-terminal iron-binding domains
(25). The primary role of transferrin is to transport iron safely
around the body to supply growing cells and plays a central
role in DNA replication with one of the key enzymes,
ribonucleotide reductase, requiring iron as a co-factor. Each
transferrin molecule can carry two Fe3+ ions and contains an
array of amino acids that are perfectly arranged to form four
bonds to the iron ion, which locks it in place (26). Transferrin
is synthesized predominantly by hepatocytes (27). Other
tissues expressing transferrin include metastatic melanoma
cell lines (28), and human breast cancer cell lines (29).
The transferrin receptor is expressed on the surface of
human cells that require iron and is responsible for
internalisation of transferrin-bound iron and its intracellular
release. Non-dividing cells can have extremely low levels of
transferrin receptor expression, whereas rapidly proliferating
cells, for example carcinoma cell lines, can express up to
100000 transferrin receptors per cell (29). In this study, the
abundance levels of the transferrin receptor were found to
be approximately 3.5-fold increased in the MDA-MB-435S-
F/Taxol-10p4pSI cells compared to the parent.
Transferrin is implicated in the growth, differentiation
and cytoprotection of many cell types. Bovine transferrin is
very abundant in serum used in the culturing of MDA-MB-
435S-F, MDA-MB-435S-F/Taxol-10p4pSI cells. The positive
growth-promoting effect of transferrin on human colon
tumour cell lines, for example, has been reported (30).
Transferrin was also found to ensure the survival of ovarian
carcinoma cells when apoptosis was induced by TNFalpha
or FasL (31), and previous publications have also implicated
transferrin in enhancing human colon tumour cell growth by
differentiation class specific mechanisms (32).
Increased expression levels of transferrin receptors could
also explain the increased abundance of the 7.6 kDa
fragment detected in MDA-MB-435S-F/Taxol-10p4pSI cells.
In this study, the fourfold increase in the detectable levels
of the 7.6 kDa bovine transferrin fragment correspond to
the 3.5-fold increase in the expression levels of the
transferrin receptor found in the MDA-MB-435S-F/Taxol-
10p4pSI population compared to MDA-MB-435S-F.
Transferrin receptor levels are elevated in various types of
cancer cells and correlate with the aggressive or
proliferative ability of tumour cells (33-35). A report also
showed that transferrin differentially stimulated the growth
of highly metastatic variant lines of murine melanoma and
that these highly metastatic cells also had greater numbers
of transferrin receptors on their cell surfaces (28). More
results suggest that neoplastic cells displaying various
metastatic properties may express differing numbers of
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Figure 6. (A) Statistical analysis for the intensity levels of the 7.6 kDa
species found to be secreted by MDA-MB-435S-F and MDA-MB-435S-
F/Taxol10p4pSI cells. (B) Statistical analysis of the transferrin receptor
from MDA-MB-435S-F and MDA-MB-435S-F/Taxol10p4pSI cells. n=5.
transferrin receptors and respond differently to growth
factors such as transferrin (29). Of recent interest was the
finding that weak or absent transferrin receptor 1 expression
in primary tumours was related to the presence of nodal or
distant metastasis in patients with colorectal cancer (36).
Previous results demonstrated that selection of the
human breast cell line MDA-MB-435S-F with paclitaxel
resulted in a more aggressively invasive phenotype (19).
Results presented here have associated this more
aggressively invasive phenotype with the increase in
expression levels of a 7.6-kDa protein fragment of
transferrin. A recent report indicates that drug resistance in
melanoma cells appears to be associated with a more
aggressive behaviour, with resistant M14 ADR cells
displaying significantly higher motility and invasion than
parental sensitive M14 WT cells. P-glycoprotein and CD44
might cooperate to confer this more invasive phenotype (8).
The results shown here suggest that SELDI-TOF MS-
based proteomic profiling may be useful in monitoring the
relationship between drug resistance and invasion/
metastasis. SELDI-TOF-MS is a recently established
technology using ProteinChip arrays to purify and detect a
selection of peptides/proteins in samples that have specific
affinity to the chromatographic surface used. SELDI-TOF-
MS is especially well suited to analyze a variety of body
fluids such as serum and also conditioned media from cell
culture. Only small sample amounts are needed for SELDI-
TOF-MS to generate data giving rapid analysis and protein
expression profiles between samples. We have demonstrated
that ProteinChip technology is a powerful proteomics
technology for elucidating differentially expressed proteins
involved in the molecular and biological processes that are
characteristic of important biological profiles, taking as
examples the drug-resistant superinvasive cell lines MDA-
MB-435S-F/Taxol-10p4pSI. The fragmentation pattern of
major serum protein generated by proteinases/enzymes
unique to specific tumours may represent a rich source of
potential biomarkers in the future. It is also possible that
cleavage of serum proteins with important roles in cell
metabolism, such as transferrin, could play a part in aspects
of cancer pathology such as tumour cachexia. 
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